argenx NV ADR (ARGX)

argenx NV ADR stock price live, this page displays NASDAQ ARGX stock exchange data. View the ARGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the argenx NV ADR real time stock price chart below.

What Is the argenx NV ADR Stock Price Today?
The argenx NV ADR stock price today is 618.00.

What Is the Stock Symbol for argenx NV ADR?
The stock ticker symbol for argenx NV ADR is ARGX.

Is ARGX the Same as $ARGX?
$ARGX is a common way to refer to the argenx NV ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol

What Stock Exchange Does argenx NV ADR Trade On?
argenx NV ADR is listed and trades on the NASDAQ stock exchange.

Is argenx NV ADR a Good Stock to Buy?
Determining whether argenx NV ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current argenx NV ADR share price compared with the fair value and other essential metrics.

You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARGX quote. (ISIN: US04016X1019)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.